NewsMarkets

Health

Study Links Imipenem/Cilastatin to Acute Kidney Injury in Critically Ill Patients

Research published in Scientific Reports associates the antibiotic imipenem/cilastatin with acute kidney injury development in critically ill patients requiring carbapenem treatment.

1 publisher · 1 article · first seen 5 Nov 2026 · updated 2d ago

Headline and summary written by an AI model from the linked article; not reviewed by a person. How this was made

This story has stopped developing; this page is its permanent record. More from that day

The story so far

1 publisher has covered this in 1 article since 5 Nov 2026. Scientific Reports published first, on 5 November at 00:00 UTC.

No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.

Sources

Every article we clustered into this story. Headlines link to the publisher.

  1. Association of imipenem/cilastatin with development of acute kidney injury in critically ill patients requiring carbapenem treatment Scientific Reports ·
Embed this story

Paste this into any web page to show the live odds, with a link back here.